# Magentiq Eye

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/magentiq-eye

- Industry: Medical Devices & Equipment
- Headquarters: Haifa, Israel
- Website: www.magentiq.com
- Latest round: Series A (Jul 30, 2025)
- Investors on record: 5

## About

Magentiq Eye Ltd., based in Israel, specializes in advanced AI-powered colonoscopy solutions, enhancing diagnostic capabilities to address colorectal cancer, a major public health concern.Founded in 2014 in Haifa, Israel, Magentiq Eye Ltd. focuses on developing innovative medical technologies for gastroenterology. The company has engaged in one funding round to date, which raised an undisclosed amount in Series A funding in July 2025, led by aMoon with participation from Norgine Ventures, Nina Capital, Namarel Ventures, and Nova Capital Partners. Details about the founder and previous ventures are not publicly available.MAGENTIQ EYE specializes in advanced AI-aided colonoscopy solutions, with its flagship product, MAGENTIQ-COLO™, leading the way in enhancing diagnostic capabilities within gastroenterology. This technology leverages artificial intelligence and machine learning to improve adenoma detection rates during colonoscopy procedures, addressing the significant public health issue of colorectal cancer. MAGENTIQ-COLO™ has been validated through extensive studies involving over 950 patients across 10 countries, showcasing improvements in clinical outcomes such as higher adenoma detection rates and reduced adenoma miss rates. The company’s customer base primarily consists of high-performing gastroenterology clinics and hospitals worldwide, particularly in regions that prioritize advanced healthcare technologies, including Europe and North America.MAGENTIQ EYE generates revenue through direct sales and partnerships with healthcare institutions utilizing its AI-aided colonoscopy technology. The company focuses on B2B sales, supplying MAGENTIQ-COLO™ systems to hospitals and gastroenterology clinics. Their revenue model is designed around a fast return on investment (ROI) framework, appealing to clients looking to enhance procedural efficiency and patient outcomes. Partnerships may also include service agreements for software updates and ongoing support, ensuring clients have access to the latest technological advancements. Specific pricing structures for their products are aligned with the value-added benefits delivered by the MAGENTIQ-COLO™ system, although specific pricing details are not disclosed. The company will use July 2025, to expand its commercial operations in the U.S. and Europe and to advance the development of artificial intelligence-based diagnostic tools and reporting features for gastrointestinal procedures. The company aims to leverage this funding to enhance its product offerings and enter new markets.

## Funding rounds

- Series A, Jul 30, 2025 — Norgine Ventures, aMoon, Nina Capital, Nova Capital Partners, Namarel Ventures

## Investors

- Norgine Ventures (https://capitalatlas.ai/funds/norgine-ventures) — Series A
- aMoon (https://capitalatlas.ai/funds/amoon) — Series A
- Nina Capital (https://capitalatlas.ai/funds/nina-capital) — Series A
- Nova Capital Partners — Series A
- Namarel Ventures (https://capitalatlas.ai/funds/namarel-ventures) — Series A